+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Pulmonary Edema Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 119 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294584
The pulmonary edema therapeutics market size is projected to be USD 3.78 billion in 2026, USD 3.92 billion in 2027, and reach USD 4.70 billion by 2032, growing at a CAGR of 3.67% from 2027 to 2032. This report is Segmented by Disease Type (Cardiogenic, Non-Cardiogenic, High-Altitude, and Infection-Induced), Drug Class (Diuretics, Vasodilators, Inotropes, Opioids, and More), Route (IV, Oral, SC, Intranasal, and Inhaled), Channel (Hospital, Retail, and Online), End User (Hospitals, and More), and Geography (North America, Europe, APAC, MEA, and South America). Forecasts in Value (USD).

Global Pulmonary Edema Therapeutics Market Trends and Insights

Rising Heart Failure and Cardiorenal Disease Burden

Heart failure and chronic kidney disease are widening the need for pulmonary edema treatment across acute and outpatient settings. The draft estimates that 6.7 million U.S. adults live with heart failure and that this number will reach 8.5 million by 2030, alongside 1.2 million annual hospitalizations related to fluid overload. Many patients also have kidney dysfunction, which can make diuretic treatment less predictable and increase the need for close dosing decisions. The U.S. Food and Drug Administration expanded the FUROSCIX label to include edema associated with chronic kidney disease in 2025, and scPharmaceuticals launched the expanded indication soon afterward. Bayer also received U.S. authorization for finerenone in adults with heart failure and an ejection fraction of 40% or more, expanding disease-modifying treatment in a group with limited earlier options. The pulmonary edema therapeutics market therefore faces a larger and more clinically complex patient base, with treatment spending increasingly linked to prevention, decongestion, and kidney monitoring.

Expansion of Non-Invasive Ventilation in Acute Care

Non-invasive ventilation is now central to the early care pathway for many patients with acute cardiogenic pulmonary edema. A 2025 review described its established role in acute respiratory failure and the growing use of high-flow nasal oxygen when face-mask interfaces are not tolerated. Treatment protocols increasingly pair ventilation with IV vasodilators and diuretics during stabilization, which supports the continued need for acute pharmacotherapy. Evidence also suggests that response is not uniform across all patients, especially older patients with different acid-base profiles. This makes patient assessment important when choosing the combination and intensity of therapy. The pulmonary edema therapeutics market benefits when acute-care protocols identify patients who need both respiratory support and rapid fluid removal.

Renal and Hemodynamic Risks of Aggressive Decongestion

Loop diuretics remain the core treatment for fluid removal, but aggressive decongestion can worsen renal function and complicate hemodynamic management. This risk is especially relevant for patients who have heart failure and chronic kidney disease at the same time. A 2025 review of decongestion therapies noted that many device-based approaches have shown limited clinical benefit, leaving drug development and clinical monitoring as central areas for improvement. Ultrasound-guided management can support better dosing decisions, but it does not remove renal risk for every patient. Clinicians are therefore likely to require standardized monitoring before they expand home-based diuresis to patients with moderate or severe kidney impairment. This constraint can slow adoption within the pulmonary edema therapeutics market even when outpatient formulations are clinically effective.

Other drivers and restraints analyzed in the detailed report include:

  1. Point-of-Care Congestion Assessment and Remote Fluid Management
  2. Growth of Home-Based Subcutaneous Diuretic Delivery
  3. High Acute-Care Costs and Diagnostic Complexity

Segment Analysis

Cardiogenic pulmonary edema held 61.43% of pulmonary edema therapeutics market revenue in 2026. This position reflects the broad population with left ventricular dysfunction, hypertensive emergencies, and valvular disease. These conditions have established treatment pathways and reimbursement support in many health systems. Sacubitril and valsartan continues to shape treatment for reduced ejection fraction heart failure, despite U.S. patent pressure. Finerenone adds a disease-modifying option for patients with mildly reduced or preserved ejection fraction after its U.S. and European authorizations. Infection-induced edema remains a smaller segment, but it draws treatment demand through ARDS management, vasopressor support, and respiratory interventions. High-altitude pulmonary edema remains specialized and is mainly managed with prevention-oriented approaches such as nifedipine and dexamethasone.

Non-cardiogenic pulmonary edema is forecast to grow at a 5.76% CAGR through 2032. ARDS creates a need for therapies that address endothelial injury and alveolar fluid accumulation, rather than supportive ventilation alone. A 2025 scientific review highlighted the lack of an approved disease-specific pharmacological standard for this condition. Edesa reported positive Phase 3 results for paridiprubart in mechanically ventilated ARDS patients during 2025. Vasomune is studying a Tie2 receptor agonist designed to stabilize the vascular barrier and limit fluid leakage. Approval of a successful late-stage candidate would materially change the treatment options for this portion of the pulmonary edema therapeutics market.

Diuretics accounted for 42.56% of pulmonary edema therapeutics market share in 2026. Generic oral and IV furosemide still support a large share of routine care, especially in hospitals and outpatient maintenance. Value is shifting toward pH-neutral subcutaneous and intranasal formulations that enable use outside traditional infusion settings. Vasodilators, including IV nitroglycerin, remain important for hypertensive acute pulmonary edema and are often used with diuretics and respiratory support. Opioids such as morphine are receiving less emphasis because of hemodynamic safety concerns. SGLT2 inhibitors, sacubitril and valsartan, and nonsteroidal mineralocorticoid receptor antagonists are also broadening the role of upstream heart failure management.

Inotropes and vasopressors are forecast to grow at a 5.99% CAGR through 2032. These treatments are important for complex presentations that combine circulatory instability, shock, and respiratory failure. AstraZeneca continues to develop cardiovascular therapies, including dapagliflozin and the investigational oral RXFP1 agonist pexerelgon. Lung-targeted therapies remain small in revenue terms, but their research activity is notable because they may address edema at the site of alveolar injury. A 2025 ATS abstract reported improved oxygenation and lower ventilator need with intratracheal tri-iodothyronine in an early study. The pulmonary edema therapeutics market could see a wider mix of acute therapies if these programs establish meaningful clinical benefit.

Complete Report Scope:

  • By Disease Type
    • Cardiogenic Pulmonary Edema
    • Non-Cardiogenic Pulmonary Edema
    • High-Altitude Pulmonary Edema
    • Infection-Induced Pulmonary Edema
  • By Drug Class
    • Diuretics
    • Vasodilators
    • Inotropes and Vasopressors
    • Opioid Analgesics
    • Heart-Failure Disease-Modifying Therapies
    • Lung-Targeted and Investigational Therapies
  • By Route of Administration
    • Intravenous
    • Oral
    • Subcutaneous
    • Sublingual and Intranasal
    • Inhaled and Aerosolized
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By End User
    • Hospitals
    • Emergency Medical Services
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Home Healthcare Settings
  • Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 42.56% of the pulmonary edema therapeutics market share in 2026. The region combines a large heart failure population, advanced emergency and inpatient infrastructure, and rapid uptake of new drug-device combinations. The FDA has supported several new delivery options, including Lasix ONYU, ENBUMYST, and Furoscix ReadyFlow. This approval activity encourages clinicians to consider treatment after discharge when patients can be monitored. The Centers for Medicare and Medicaid Services is also reshaping incentives through proposed models that focus on avoidable heart failure admissions. Canada supports stable access to loop diuretics through its public health system, while Mexico offers growth for generic IV medicines as hospital capacity improves. Regulatory influence from the FDA and reimbursement policy remain important to regional adoption.

Asia-Pacific is forecast to grow at a 4.65% CAGR through 2032. Hospital investment across China, India, and Southeast Asia is expanding access to intensive care beds, IV drugs, and emergency treatment capabilities. Growing awareness of acute decompensated heart failure is also improving the route from diagnosis to treatment. Lung ultrasound and AI-assisted radiology may be useful where cardiology capacity is limited and emergency imaging expertise is still developing. A review and meta-analysis reported that lung-ultrasound-guided therapy reduced major adverse cardiovascular events, supporting wider evaluation of this approach. Japan and South Korea are adopting more disease-modifying heart failure therapies, which may reduce severe admissions while expanding chronic care. Health-system investment and clinician training will decide how quickly new delivery technologies reach the broader pulmonary edema therapeutics market in the region.

Europe has established heart failure pathways, clinical evidence networks, and biomarker-led emergency care, while the Middle East, Africa, and South America show more uneven access. Bayer received European Commission and UK authorization for finerenone in March 2026 for adults with heart failure and left ventricular ejection fraction of 40% or more. Germany, the United Kingdom, and France have active specialist networks that can adopt subcutaneous diuretics as outpatient programs formalize discharge goals. Gulf Cooperation Council countries are increasing intensive care capacity and specialist access, but branded therapies remain less accessible beyond major cities. Brazil and Argentina are improving acute respiratory care infrastructure, although treatment costs and coverage gaps still limit spending per episode. European regulatory decisions, national reimbursement rules, and hospital procurement systems will influence adoption across these mixed geography segments. The pulmonary edema therapeutics market will therefore grow at different speeds across mature specialist centers and resource-constrained systems.



List of Companies Covered in this Report:

  1. AstraZeneca
  2. B. Braun
  3. Baxter
  4. Bayer
  5. Boehringer Ingelheim
  6. Cipla
  7. Dr. Reddy’s Laboratories
  8. Fresenius
  9. Hikma Pharmaceuticals
  10. Johnson & Johnson
  11. Lupin
  12. MannKind
  13. Merck
  14. Novartis
  15. Pfizer
  16. Sanofi
  17. Sun Pharmaceuticals Industries
  18. Teva Pharmaceutical Industries
  19. Viatris

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope Of The Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Heart Failure and Cardiorenal Disease Burden
4.2.2 Expansion of Non-Invasive Ventilation in Acute Care
4.2.3 Point-of-Care Pulmonary Congestion Assessment
4.2.4 Growth of Home-Based Subcutaneous Diuretic Delivery
4.2.5 Biomarker-Guided and Remote Fluid Management
4.2.6 Lung-Targeted Therapies for Permeability Edema
4.3 Market Restraints
4.3.1 Renal and Hemodynamic Risks of Aggressive Decongestion
4.3.2 High Acute-Care and Hospitalization Costs
4.3.3 Diagnostic Overlap Across Cardiac, Pulmonary, and Infectious Causes
4.3.4 Limited Disease-Specific Therapy for Non-Cardiogenic Edema
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat Of New Entrants
4.7.2 Bargaining Power Of Buyers
4.7.3 Bargaining Power Of Suppliers
4.7.4 Threat Of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Disease Type
5.1.1 Cardiogenic Pulmonary Edema
5.1.2 Non-Cardiogenic Pulmonary Edema
5.1.3 High-Altitude Pulmonary Edema
5.1.4 Infection-Induced Pulmonary Edema
5.2 By Drug Class
5.2.1 Diuretics
5.2.2 Vasodilators
5.2.3 Inotropes and Vasopressors
5.2.4 Opioid Analgesics
5.2.5 Heart-Failure Disease-Modifying Therapies
5.2.6 Lung-Targeted and Investigational Therapies
5.3 By Route of Administration
5.3.1 Intravenous
5.3.2 Oral
5.3.3 Subcutaneous
5.3.4 Sublingual and Intranasal
5.3.5 Inhaled and Aerosolized
5.4 By Distribution Channel
5.4.1 Hospital Pharmacies
5.4.2 Retail Pharmacies
5.4.3 Online Pharmacies
5.5 By End User
5.5.1 Hospitals
5.5.2 Emergency Medical Services
5.5.3 Specialty Clinics
5.5.4 Ambulatory Surgical Centers
5.5.5 Home Healthcare Settings
5.6 Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles {(Includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)}
6.3.1 AstraZeneca PLC
6.3.2 B. Braun SE
6.3.3 Baxter International Inc.
6.3.4 Bayer AG
6.3.5 Boehringer Ingelheim International GmbH
6.3.6 Cipla Limited
6.3.7 Dr. Reddy's Laboratories Ltd.
6.3.8 Fresenius SE & Co. KGaA
6.3.9 Hikma Pharmaceuticals PLC
6.3.10 Johnson & Johnson
6.3.11 Lupin Limited
6.3.12 MannKind Corporation
6.3.13 Merck & Co., Inc.
6.3.14 Novartis AG
6.3.15 Pfizer Inc.
6.3.16 Sanofi
6.3.17 Sun Pharmaceutical Industries Limited
6.3.18 Teva Pharmaceutical Industries Ltd.
6.3.19 Viatris Inc.
7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca PLC
  • B. Braun SE
  • Baxter International Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Lupin Limited
  • MannKind Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.